New England Journal of Medicine· 2022Q1· Clinical trial

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman et al.

5,328citations
Q1SCImago
2022year

Short summary

The drug lecanemab, a monoclonal antibody targeting amyloid-beta protofibrils, demonstrated a modest slowing of cognitive and functional decline by 0.45 points on the CDR-SB scale over 18 months in early Alzheimer's patients compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Physiology

PhysiologyMedicine